The recombinant hepatitis B vaccine has received its first regulatory approval in Belgium. SmithKline announced in late October that it had finalized its exclusive licensing agreement with the Institut Pasteur covering the Engerix-B vaccine. Developed and produced by SmithKline's Brussels-based biologicals subsidiary, SmithKline-RIT, Engerix-B has been studied in over 6,000 patients in clinical studies in 15 countries. SmithKline said that Engerix-B is "expected to be approved and marketed in many countries in Europe, Southeast Asia and Africa within the next year".
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.